A Remarkable Medicine Has Been Overlooked, and The Broad Range of Clinical Use of Phenytoin: Bioelectric Modulator, by the Dreyfus Medical Foundation
Over 10,000 studies from 38 countries, published in over 250 medical journals form the basis of the Bibliography and Review.
In 1908, a German chemist, Heinrich Biltz, synthesized diphenylhydantoin (phenytoin, of PHT). Biltz sold PHT along with other compounds, to Parke-Davis, which did not patent it or find a use for it for 25 years. In 1937, two doctors outside Parke-Davis discovered PHT's first use, for epilepsy, for which it was more effective than Phenobarbital.
Basic mechanism studies demonstrate that phenytoin corrects inappropriate electrical activity at the level of a single cell -- with little or no effect on normal cell function. This fundamental property makes clear how one drug can be useful for over fifty symptoms and disorders.
Phenytoin's only listing with the FDA is as an anticonvulsant. PHT is a prescription medicine which should be obtained through a physician.
There is a flaw in our system of bringing prescription medicines to the public.
"The FDA does not limit the manner in which a physician may use an approved drug. Once a product has been approved for marketing, a physician may prescribe it for uses or in treatment regimens that are not included in approved labeling. Some 'unapproved' or, more precisely, unlabeled uses may, in fact, reflect approaches to drug therapy that have been extensively reported in medical literature."
Phenytoin, also known generically as diphenylhydantoin or PHT has many trade names. In the U.S. it's best known name is Dilantin. Other trade names outside the US include Aleviaton, Epamin, Epanutin, Epelin, Eptoin, Hidantal, Idantoin, Phenhydan, Solantyl.
PHT has regulatory effects on endocrine and metabolic processes, and on stress. It has been demonstrated to have anti-anoxic effects, anti-toxic properties, and to promote healing.
PHT is not habit forming. Safety parameters have been established over 50 years of extensive and intensive use.
"Jack Dreyfus founded the Dreyfus Medical Foundation over 35 years ago to study, collect, and disseminate current information and sponsor new research on the clinical uses of PHT."
info provided by